Primary cervical cancer screening with HPV testing compared with liquid-based cytology: Results of round 1 of a randomised controlled trial-the HPV FOCAL Study

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 1917-1924

  Ogilvie, G S ^a,b   Krajden, M ^a,b   Van Niekerk, D J ^a,c   Martin, R E ^a   Ehlen, T G ^a   Ceballos, K ^a,c   Smith, L W ^c   Kan, L ^c   Cook, D A ^b   Peacock, S ^c   Stuart, G C E ^a   Franco, E L ^d   Coldman, A J ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

cervical cancer; HPV; North America; randomised trial; screening

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; ALGORITHMS; ALPHAPAPILLOMAVIRUS; CANADA; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SEXUAL PARTNERS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84870815000     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.489     Document Type: Article

References (16)

1. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P,Tarkkanen J, Malila N, Nieminen P (2010) Rate of cervical cancer, severeintraepithelial neoplasia, and adenocarcinoma in situ in primary HPVDNA screening with cytology triage: randomised study within organisedscreening programme. BMJ 340: c1804
2. Castle PE (2010) Screening: HPV testing for cervical cancer: the good, thebad, and the ugly. Nat Rev Clin Oncol 7: 364-365
3. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH,Dillner J, Meijer CJ (2008) Overview of human papillomavirus-based andother novel options for cervical cancer screening in developed anddeveloping countries. Vaccine 26(Suppl 10): K29-K41
4. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C,de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van BallegooijenM, Clavel C, Iftner T, Joint European CS (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancerscreening: joint European cohort study. BMJ 337: a1754
5. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM (2009) EUROGIN2008 roadmap on cervical cancer prevention. Int J Cancer 125: 2246-2255
6. Franco EL, Cuzick J (2008) Cervical cancer screening following prophylactichuman papillomavirus vaccination. Vaccine 2008: 16-23
7. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W,Paraskevaidis E (2006) Obstetric outcomes after conservative treatmentfor intraepithelial or early invasive cervical lesions: systematic reviewand meta-analysis. Lancet 367: 489-498
8. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J,Laurila P, Anttila A (2009) Age-specific evaluation of primary humanpapillomavirus screening vs conventional cytology in a randomizedsetting. J Natl Cancer Inst 101: 1612-1623
9. Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K,Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL,Coldman AJ (2010) A randomized controlled trial of Human Papillomavirus(HPV) testing for cervical cancer screening: trial design andpreliminary results (HPV FOCAL Trial). BMC Cancer 10: 111
10. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla PP, Naldoni C,Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, SchiboniML, Sintoni C, Zorzi M, Segnan N, Confortini M (2007) Accuracyof liquid based versus conventional cytology: overall results of newtechnologies for cervical cancer screening: randomised controlled trial.[see comment]. BMJ 335: 28
11. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del Mistro A,Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, PierottiP, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J (2010)Efficacy of human papillomavirus testing for the detection of invasivecervical cancers and cervical intraepithelial neoplasia: a randomisedcontrolled trial. Lancet Oncol 11: 249-257
12. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla PP, Del Mistro A, De Marco L,De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P,Zorzi M, Confortini M, Cuzick J, New Technologies for Cervical CancerScreening Working GroupNew Technologies for Cervical Cancer ScreeningWorking Group (2006) Human papillomavirus testing and liquidbasedcytology in primary screening of women younger than 35 years:results at recruitment for a randomised controlled trial. Lancet Oncol 7:547-555
13. Siebers AG, Klinkhamer PJJM, Grefte JMM, Massuger LFAG, Vedder JEM,Beijers-Broos A, Bulten J, Arbyn M (2009) Comparison of liquid-basedcytology with conventional cytology for detection of cervical cancerprecursors: a randomized trial. JAMA 302: 1757-1764
14. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M,Raab S, Sherman M, Wilbur D, Wright Jr T, Young N, ForumGroup, Bethesda 2001 Workshop (2002) The 2001 Bethesda System:terminology for reporting results of cervical cytology. JAMA 287:2114-2119
15. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirusis a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19
16. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU (2011)Liquid-based cytology and Human Papillomavirus testing to screen forcervical cancer: a systematic review for the US Preventive Services TaskForce. Ann Intern Med 155(10): 687-697, W214-5